Attomarker
Generated by Meeveem AI
"Multiplexed blood testing for personalised diagnostics in immunology and infection"
Exeter
•11 - 50 Employees
•Diagnostics
About Attomarker
Attomarker develops precision diagnostic technology that measures multiple biomarkers from a single blood sample in under 10 minutes. Built on gold nanoparticle nanotechnology from the University of Exeter, the platform delivers quantitative results at point of care. The CE marked system identifies three immune endotypes in Long COVID patients, enabling tailored treatment. The company addresses gaps in immunology and infection diagnostics. Healthcare professionals gain actionable data to guide decisions, while patients with Long COVID and complex immune conditions benefit from personalised care. This matters because biological subtypes transform outcomes like cancer treatment evolved from generic to targeted therapies.
11
Team Members
2008
Founded
Diagnostics
Sector
On-Site
Work Environment
Our Vision
A world where every patient receives diagnostics precise enough to reveal their unique biological profile, enabling healthcare that treats the individual rather than the average, and where immune complexity is understood rather than simplified.
Our Mission
At Attomarker, our mission is to make high quality diagnostics accessible to all, bridging the gap between laboratory precision and real world healthcare needs.